0.9708
Fate Therapeutics Inc stock is traded at $0.9708, with a volume of 1.28M.
It is down -3.88% in the last 24 hours and down -10.94% over the past month.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
See More
Previous Close:
$1.01
Open:
$1
24h Volume:
1.28M
Relative Volume:
0.88
Market Cap:
$111.96M
Revenue:
$13.45M
Net Income/Loss:
$-178.23M
P/E Ratio:
-0.5884
EPS:
-1.65
Net Cash Flow:
$-132.53M
1W Performance:
-2.92%
1M Performance:
-10.94%
6M Performance:
+7.54%
1Y Performance:
-71.86%
Fate Therapeutics Inc Stock (FATE) Company Profile
Name
Fate Therapeutics Inc
Sector
Industry
Phone
858.875.1803
Address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
FATE
Fate Therapeutics Inc
|
0.9708 | 116.48M | 13.45M | -178.23M | -132.53M | -1.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
381.87 | 96.56B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
449.58 | 60.08B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
555.51 | 61.15B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ARGX
Argen X Se Adr
|
711.09 | 44.66B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
328.71 | 36.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-18-24 | Upgrade | BofA Securities | Underperform → Neutral |
Jun-17-24 | Upgrade | Piper Sandler | Neutral → Overweight |
Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
Jan-24-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
Jan-06-23 | Downgrade | Cowen | Outperform → Market Perform |
Jan-06-23 | Downgrade | Piper Sandler | Overweight → Neutral |
Jan-06-23 | Downgrade | Stifel | Buy → Hold |
Jan-06-23 | Downgrade | Truist | Buy → Hold |
Jan-06-23 | Downgrade | Wedbush | Outperform → Neutral |
Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
Dec-15-22 | Initiated | Goldman | Sell |
Nov-04-22 | Resumed | Cantor Fitzgerald | Overweight |
Oct-10-22 | Initiated | Canaccord Genuity | Buy |
Aug-18-22 | Resumed | Wells Fargo | Overweight |
Jul-28-22 | Initiated | Needham | Hold |
Jul-11-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Jun-03-22 | Initiated | Robert W. Baird | Neutral |
Feb-11-22 | Resumed | BMO Capital Markets | Market Perform |
Dec-15-21 | Upgrade | Wedbush | Neutral → Outperform |
Dec-07-21 | Initiated | Cowen | Outperform |
Nov-09-21 | Upgrade | Citigroup | Neutral → Buy |
Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
Jun-07-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
May-07-21 | Upgrade | Wedbush | Neutral → Outperform |
Apr-26-21 | Resumed | Jefferies | Buy |
Feb-26-21 | Initiated | BofA Securities | Buy |
Feb-26-21 | Downgrade | Wedbush | Outperform → Neutral |
Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
Jan-27-21 | Resumed | H.C. Wainwright | Neutral |
May-13-20 | Initiated | H.C. Wainwright | Buy |
Mar-04-20 | Initiated | Barclays | Overweight |
Jan-09-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Dec-30-19 | Reiterated | Mizuho | Buy |
Dec-09-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
Nov-12-19 | Initiated | SunTrust | Buy |
Nov-06-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
Oct-01-19 | Initiated | Stifel | Buy |
Aug-09-19 | Initiated | BTIG Research | Buy |
Jul-22-19 | Initiated | Cantor Fitzgerald | Overweight |
Jul-12-19 | Initiated | Oppenheimer | Outperform |
Jun-13-19 | Initiated | Mizuho | Buy |
Jun-07-19 | Initiated | ROTH Capital | Neutral |
May-31-19 | Initiated | Guggenheim | Buy |
May-24-19 | Resumed | Citigroup | Buy |
Mar-28-19 | Initiated | SVB Leerink | Outperform |
Jan-03-19 | Downgrade | Stephens | Overweight → Equal-Weight |
Nov-05-18 | Initiated | Jefferies | Buy |
Aug-01-18 | Initiated | Citigroup | Buy |
Mar-06-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
View All
Fate Therapeutics Inc Stock (FATE) Latest News
Fate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat
Fate Therapeutics Inc. stock daily chart insightsJuly 2025 Selloffs & Weekly Watchlist for Consistent Profits - newser.com
Stem Cell Co. Beats Investor Suit Over Failed Janssen Collab - Law360
Fate Therapeutics Gets J&J Partnership Class Action Tossed Again - Bloomberg Law News
Top chart patterns to watch in Fate Therapeutics Inc.Insider Buying & AI Enhanced Trade Execution Alerts - newser.com
Evaluating Fate Therapeutics Inc. with trendline analysisWeekly Trend Summary & AI Driven Price Predictions - newser.com
Fate Therapeutics, Inc. $FATE Shares Bought by Acadian Asset Management LLC - MarketBeat
Applying big data sentiment scoring on Fate Therapeutics Inc.2025 EndofYear Setup & Growth Focused Stock Pick Reports - newser.com
Options Flow: Can Fate Therapeutics Inc ride the EV waveIndex Update & Weekly Setup with ROI Potential - خودرو بانک
Aug PreEarnings: Is Fate Therapeutics Inc. subject to activist investor interestTrend Reversal & Fast Entry High Yield Stock Tips - خودرو بانک
Will Fate Therapeutics Inc. rebound enough to break even2025 Technical Overview & Daily Stock Trend Watchlist - newser.com
Aug PostEarnings: Is Fate Therapeutics Inc in a bullish channel2025 Retail Activity & Consistent Growth Equity Picks - خودرو بانک
Using Ichimoku Cloud for Fate Therapeutics Inc. technicalsEarnings Beat & Technical Entry and Exit Alerts - newser.com
Insider Buy: What is the dividend yield of Fate Therapeutics IncQuarterly Portfolio Review & AI Driven Stock Price Forecasts - khodrobank.com
MACD Signal: Is Fate Therapeutics Inc subject to activist investor interest2025 Macro Impact & Fast Moving Market Watchlists - khodrobank.com
Signal strength of Fate Therapeutics Inc. stock in tech scannersStop Loss & Accurate Entry/Exit Alerts - newser.com
Breakout Zone: Is Fate Therapeutics Incs ROIC above industry averageGlobal Markets & Real-Time Market Trend Scan - khodrobank.com
Short Covering: Is Fate Therapeutics Inc subject to activist investor interestJuly 2025 Breakouts & Growth Focused Stock Reports - خودرو بانک
Should you wait for a breakout in Fate Therapeutics Inc.2025 Top Decliners & Safe Capital Growth Tips - newser.com
Fed Meeting: Is Fate Therapeutics Inc stock risky to hold nowWeekly Investment Recap & Risk Managed Investment Strategies - خودرو بانک
Portfolio Shifts: Is Fate Therapeutics Inc showing insider buyingMarket Movers & Weekly Stock Performance Updates - خودرو بانک
Analyst Upgrade: Is Fate Therapeutics Inc showing insider buyingWeekly Investment Summary & AI Driven Stock Price Forecasts - khodrobank.com
Trading Recap: Is Fate Therapeutics Inc in a bullish channelJuly 2025 Setups & Free AI Powered Buy and Sell Recommendations - خودرو بانک
Risk Report: Will Fate Therapeutics Inc outperform the market in YEARMarket Movers & Verified Chart Pattern Signals - خودرو بانک
Jacobs Levy Equity Management Inc. Acquires 616,336 Shares of Fate Therapeutics, Inc. $FATE - MarketBeat
What analysts say about Fate Therapeutics Inc stockJuly 2025 Recap & High Yield Stock Recommendations - خودرو بانک
Hedge Fund Bets: Can Fate Therapeutics Inc lead its sector in growth2025 Technical Patterns & Smart Swing Trading Techniques - خودرو بانک
Momentum Shift: Is Fate Therapeutics Inc stock risky to hold now2025 Fundamental Recap & Reliable Breakout Forecasts - خودرو بانک
Activity Recap: What is the dividend yield of Fate Therapeutics Inc2025 Major Catalysts & Safe Capital Allocation Plans - خودرو بانک
Stock Report: Will Fate Therapeutics Inc outperform the market in YEAR2025 Institutional Moves & Technical Buy Zone Confirmation - خودرو بانک
How to read the order book for Fate Therapeutics Inc.Global Markets & Community Shared Stock Ideas - newser.com
Should you hold or exit Fate Therapeutics Inc. nowJuly 2025 EndofMonth & Weekly Top Gainers Alerts - newser.com
Walleye Capital LLC Sells 1,010,806 Shares of Fate Therapeutics, Inc. $FATE - MarketBeat
Nuveen LLC Purchases Shares of 379,088 Fate Therapeutics, Inc. $FATE - MarketBeat
Leerink Partnrs Analysts Raise Earnings Estimates for FATE - MarketBeat
Will Fate Therapeutics Inc. outperform small cap indexesJuly 2025 Chart Watch & Comprehensive Market Scan Reports - Lancaster City Council
RSI + MACD Show Convergence for Fate Therapeutics Inc.2025 Dividend Review & Weekly Stock Breakout Alerts - beatles.ru
Analysts Set Fate Therapeutics, Inc. (NASDAQ:FATE) Price Target at $3.30 - MarketBeat
Price Floor Holding on Fate Therapeutics Inc. — Rebound PossibleJuly 2025 Summary & Verified Short-Term Trading Plans - beatles.ru
Using data models to predict Fate Therapeutics Inc. stock movementEarnings Recap Summary & Consistent Return Investment Signals - Newser
Volume spikes in Fate Therapeutics Inc. stock – what they meanGlobal Markets & Risk Adjusted Swing Trade Ideas - Newser
Heatmap analysis for Fate Therapeutics Inc. and competitorsJuly 2025 Gainers & Free Safe Entry Trade Signal Reports - Newser
Visual trend scoring systems applied to Fate Therapeutics Inc.Market Trend Report & AI Optimized Trading Strategy Guides - Newser
What MACD and RSI say about Fate Therapeutics Inc.July 2025 Macro Moves & Reliable Volume Spike Trade Alerts - Newser
Leerink Partners Sticks to Its Buy Rating for Fate Therapeutics (FATE) - The Globe and Mail
Layoff Tracker: AC Immune To Cut 30% of Workforce - BioSpace
Can technical indicators confirm Fate Therapeutics Inc.’s reversalSwing Trade & Stock Market Timing Techniques - Newser
What are analysts’ price targets for Fate Therapeutics Inc.2025 Market Overview & Smart Swing Trading Alerts - خودرو بانک
Key metrics from Fate Therapeutics Inc.’s quarterly dataEarnings Recap Summary & Safe Investment Capital Preservation Plans - Newser
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Fate Therapeutics Inc Stock (FATE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):